Core Viewpoint - Rosen Law Firm is reminding purchasers of Semler Scientific, Inc. securities about the lead plaintiff deadline for a securities class action lawsuit, emphasizing the potential for compensation without upfront costs for eligible investors [1][2]. Group 1: Class Action Details - The class action pertains to securities purchased between March 10, 2021, and April 15, 2025, with a lead plaintiff deadline set for October 28, 2025 [1]. - Investors who wish to join the class action can do so through a provided link or by contacting the firm directly [3][6]. - A class action lawsuit has already been filed, and interested parties must act by the specified deadline to serve as lead plaintiff [3]. Group 2: Legal Background - The lawsuit alleges that Semler Scientific made materially false and misleading statements and failed to disclose a significant investigation by the U.S. Department of Justice regarding violations of the False Claims Act [5]. - The claims suggest that the defendants' public statements were misleading, leading to investor damages when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for securities fraud, related to safety issues with its Novum IQ Large Volume Pump, which has led to significant stock price decline and investor losses [1][5][6]. Summary by Sections Lawsuit Announcement - The Law Offices of Frank R. Cruz are encouraging Baxter shareholders to inquire about a class action lawsuit filed on behalf of investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025 [1][2]. Safety Issues - On April 7, 2025, a Missouri news outlet reported serious safety concerns regarding Baxter's Novum IQ Large Volume Pump, citing a whistleblower who claimed the pumps were unsafe for patient treatment [3]. - Following this, Baxter issued warning letters about potential underinfusion risks, later revealing 79 reports of serious injuries and two patient deaths associated with the device [4]. Stock Price Impact - On July 31, 2025, Baxter announced a voluntary pause on shipments and installations of the Novum LVP, resulting in a stock price drop of $6.24, or 22.4%, closing at $21.61 per share [5]. Allegations in the Lawsuit - The lawsuit alleges that Baxter made materially false and misleading statements and failed to disclose critical information about the Novum LVP's systemic defects, which posed risks of serious injury or death to patients [6][7]. - Specific allegations include the company's knowledge of device malfunctions, inadequate remedial measures, and misleading positive statements about its business prospects [7].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX) for securities fraud, following disappointing Phase 3 results for its drug candidate sonelokimab (SLK) [1][3]. Summary by Sections Lawsuit Announcement - The Law Offices of Frank R. Cruz announced a class action lawsuit on behalf of shareholders who purchased MLTX common stock between March 10, 2024, and September 29, 2025, with a deadline of December 15, 2025, for filing a lead plaintiff motion [1]. Disappointing Drug Results - On September 28, 2025, MoonLake announced that SLK failed to match the efficacy of its competitor's drug, BIMZELX, despite prior claims of its superiority [3]. - The company had promoted SLK's nanobody structure as superior but allegedly did not disclose that it targeted the same molecules as BIMZELX and lacked proven advantages [3]. Stock Price Impact - Following the announcement of the disappointing results, MoonLake's stock plummeted by $55.74, or 89.9%, closing at $6.24 per share on September 29, 2025, significantly harming investors [4]. Allegations in the Lawsuit - The lawsuit alleges that during the Class Period, the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, including: 1. SLK and BIMZELX share the same molecular targets [5]. 2. SLK's nanobody structure would not provide superior clinical benefits over BIMZELX [5]. 3. The supposed increased tissue penetration of SLK would not translate to clinical efficacy [5]. 4. Positive statements about the company's business were materially misleading and lacked a reasonable basis [5].

Core Viewpoint - The James Hardie Industries plc is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors about its sales performance during a period of inventory destocking [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled "Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc" and covers purchasers of James Hardie common stock from May 20, 2025, to August 18, 2025 [1]. - Investors have until December 23, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that James Hardie executives made false statements about the strength of the North America Fiber Cement segment, despite evidence of inventory destocking [3]. Group 2: Financial Impact - On August 19, 2025, James Hardie disclosed a 12% decline in sales in the North America Fiber Cement segment, attributed to customer destocking [4]. - Following this disclosure, the company's stock price dropped by over 34% [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased James Hardie common stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff will represent the interests of all class members and can choose a law firm for litigation [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [6].

Core Viewpoint - A class-action lawsuit has been filed against James Hardie Industries plc, alleging securities fraud related to misleading statements about inventory levels and customer demand in its North American segment [1][3][5]. Group 1: Lawsuit Details - The lawsuit, titled Laborers' District Council & Contractors' Pension Fund of Ohio v. James Hardie Industries PLC, covers a class period from May 20, 2025, to August 18, 2025, and seeks damages for violations of the Securities Exchange Act of 1934 [2][4]. - The lead plaintiff deadline is set for December 23, 2025, and the lawsuit is filed on behalf of all investors who purchased James Hardie common stock during the specified class period [2]. Group 2: Allegations Against the Company - The complaint centers on the North America Fiber Cement segment, which accounts for approximately 80% of James Hardie's total earnings [3]. - Plaintiffs allege that management denied significant inventory destocking trends observed in April and May 2025, misleading investors about the segment's strength [3][4]. - Executives allegedly made false statements around May 20 and 21, 2025, claiming robust customer demand while denying inventory destocking, which concealed underlying sales issues [4]. Group 3: Impact of the Allegations - On August 19, 2025, James Hardie disclosed a 12% decline in sales for the North America Fiber Cement division, attributing it to the customer destocking previously denied [5]. - Following this disclosure, the company's stock price fell by over 34%, leading to significant losses for investors [6]. - The lawsuit aims to recover damages for investors who suffered financial injuries due to the alleged wrongful acts during the class period [6].

Core Viewpoint - James Hardie Industries plc is facing a class action lawsuit for securities fraud, with allegations of false and misleading statements regarding its business performance, particularly in the North America Fiber Cement sector [5]. Summary by Sections Class Action Lawsuit - The Schall Law Firm is leading a class action lawsuit against James Hardie Industries plc for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased securities between May 20, 2025, and August 18, 2025, are encouraged to contact the firm before December 23, 2025 [2]. Allegations and Company Performance - The lawsuit claims that James Hardie made false statements about strong demand and normal inventory levels, despite knowing about weakening demand due to distributors destocking their inventory by early May 2025 [5]. - The company reported a 12% sales decline in its North America Fiber Cement business on August 19, 2025, attributing it to "normalization of channel inventories," which the lawsuit argues was misleading [5].

Core Viewpoint - Semler Scientific Inc. is facing a securities fraud class action lawsuit due to alleged misleading statements and failure to disclose material facts regarding investigations by the U.S. Department of Justice [4][5]. Group 1: Lawsuit Details - The lawsuit is based on claims that Semler made materially false and misleading statements about its business and operations during the class period from March 10, 2021, to April 15, 2025 [4]. - The company disclosed a risk of a DOJ complaint related to its QuantaFlo device and acknowledged an initial civil investigative demand from the DOJ dating back to July 2017 [2][4]. - Following the announcement of a settlement agreement with the DOJ for $29.75 million, Semler's stock price fell significantly, indicating investor injury [3]. Group 2: Financial Impact - On March 3, 2025, Semler's stock price dropped by $4.03, or 9.4%, closing at $38.89 per share after the DOJ news [3]. - After the April 15, 2025 announcement regarding the settlement, the stock price fell by $3.40, or 9.9%, closing at $31.00 per share [3]. Group 3: Investor Participation - Investors who acquired Semler securities during the class period are urged to participate in the class action lawsuit, with a deadline set for October 28, 2025, to seek lead plaintiff status [5].

Core Viewpoint - A class action lawsuit has been filed against Marex Group plc, alleging that the company concealed losses and inflated profits through deceptive financial practices during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague on behalf of investors who purchased Marex shares from May 16, 2024, to August 5, 2025 [1][2]. - Investors have until December 8, 2025, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations and Impact - NINGI Research published a report on August 5, 2025, claiming that Marex used off-balance-sheet entities and fictitious intercompany transactions to hide losses and inflate profits [3]. - Following the report, Marex's stock price fell by $2.33, or 6.2%, closing at $35.31, resulting in significant investor losses [3].

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the sale of Essential Utilities, Inc. to American Water Works Company, Inc. for 0.305 shares of American Water for each share of Essential [1] Group 1: Investigation Details - The investigation focuses on whether Essential and its board violated federal securities laws and/or breached fiduciary duties to shareholders [3] - Key concerns include whether the best possible consideration was obtained for shareholders, if American Water is underpaying for Essential, and if all material information was disclosed for shareholders to assess the merger [3] Group 2: Potential Actions - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief related to the proposed transaction [4] - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [4]

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for allegedly violating federal securities laws by issuing false and misleading statements regarding its business and operations [1][2]. Summary by Sections Allegations - The lawsuit claims that James Hardie Industries misled investors about the performance of its North America Fiber Cement segment from May 20 to August 18, 2025, despite knowing about inventory destocking by distributors [2]. - The company falsely asserted that demand was strong and inventory levels were "normal" during this period [2]. Financial Impact - On August 19, 2025, James Hardie reported a 12% sales decline in the North America Fiber Cement segment, attributing it to "normalization of channel inventories" and warned of ongoing weakness [2]. - Following this announcement, the company's share price dropped over 34%, resulting in significant losses for investors [2]. Legal Proceedings - The lawsuit is filed in the Northern District of Illinois and is titled Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc [3]. - It represents all individuals who purchased or acquired James Hardie Industries common stock between May 20, 2025, and August 18, 2025 [3].